U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C21H16ClF3N4O3
Molecular Weight 464.825
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SORAFENIB

SMILES

CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1

InChI

InChIKey=MLDQJTXFUGDVEO-UHFFFAOYSA-N
InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)

HIDE SMILES / InChI

Molecular Formula C21H16ClF3N4O3
Molecular Weight 464.825
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20812347 https://www.ncbi.nlm.nih.gov/pubmed/16757355

Sorafenib (BAY 43-9006), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer, hepatocellular carcinoma and for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment. It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib was shown to interact with multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, VEGFR- 2, VEGFR- 3, and PDGFR- ß). Several of these kinases are thought to be involved in angiogenesis. Thus, sorafenib may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling). Sorafenib inhibited tumor growth of the murine renal cell carcinoma, RENCA, and several other human tumor xenografts in athymic mice. A reduction in tumor angiogenesis was seen in some tumor xenograft models.

CNS Activity

Curator's Comment: Sorafenib effectively crosses the blood-brain barrier and inhibits tumor growth in an orthotopic tumor model of glioblastoma

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NEXAVAR

Approved Use

NEXAVAR is a kinase inhibitor indicated for the treatment of •Unresectable hepatocellular carcinoma (1.1) •Advanced renal cell carcinoma (1.2) •Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment (1.3) 1.1 Hepatocellular Carcinoma NEXAVAR® is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). 1.2 Renal Cell Carcinoma NEXAVAR is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). 1.3 Differentiated Thyroid Carcinoma NEXAVAR is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Launch Date

2005
Primary
NEXAVAR

Approved Use

NEXAVAR is a kinase inhibitor indicated for the treatment of •Unresectable hepatocellular carcinoma (1.1) •Advanced renal cell carcinoma (1.2) •Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment (1.3) 1.1 Hepatocellular Carcinoma NEXAVAR® is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). 1.2 Renal Cell Carcinoma NEXAVAR is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). 1.3 Differentiated Thyroid Carcinoma NEXAVAR is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Launch Date

2005
Primary
NEXAVAR

Approved Use

NEXAVAR is a kinase inhibitor indicated for the treatment of •Unresectable hepatocellular carcinoma (1.1) •Advanced renal cell carcinoma (1.2) •Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment (1.3) 1.1 Hepatocellular Carcinoma NEXAVAR® is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). 1.2 Renal Cell Carcinoma NEXAVAR is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). 1.3 Differentiated Thyroid Carcinoma NEXAVAR is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Launch Date

2005
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9.35 μg/mL
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.31 μg/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
9.81 μg/mL
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.21 μg/mL
800 mg 2 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.44 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
3.42 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.98 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.69 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3.1 μg/mL
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.8 μg/mL
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.43 mg/L
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
71.7 mg × h/L
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
23.8 mg × h/L
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
79 mg × h/L
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
44.9 mg × h/L
800 mg 2 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
82.3 mg × h/L
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
106.98 mg × h/L
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
49.8 mg × h/L
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
83.8 mg × h/L
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.6 μg × h/mL
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
17.9 μg × h/mL
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
9.4 mg × h/L
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
28.1 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
23.8 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
37.9 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
28.9 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
27.1 h
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.31%
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.29%
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SORAFENIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
DLT: Hypertension, Rash...
Other AEs: Dyspnea, Rash...
Dose limiting toxicities:
Hypertension (grade 3, 33%)
Rash (grade 2, 33%)
Rash (grade 3, 67%)
Other AEs:
Dyspnea (grade 3, 33%)
Rash (grade 3, 67%)
Fatigue (grade 1, 67%)
Anorexia (grade 1, 33%)
Nausea (grade 1, 33%)
Pharyngitis (grade 1, 33%)
Dyspnea (grade 3, 33%)
Pruritis (grade 1, 67%)
Sources:
600 mg 2 times / day multiple, oral
MTD
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Other AEs: Ascites, Constipation...
Other AEs:
Ascites (grade 3, 33%)
Constipation (grade 3, 17%)
Obstruction ureter (grade 3, 17%)
Hypoalbuminemia (grade 3, 17%)
Alkaline phosphatase (grade 3, 33%)
Muscle weakness (grade 3, 17%)
Depressed level of consciousness (grade 3, 17%)
Pleural effusion (grade 3, 17%)
Hypoxia (grade 3, 17%)
Pruritis (grade 1, 17%)
Rash (grade 1, 17%)
Hypocalcemia (grade 1, 17%)
Sources:
800 mg 2 times / day multiple, oral
Highest studied dose
unhealthy, Median age 57 years
Other AEs: Diarrhea...
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Median age 57 years
Other AEs: Hand and foot skin reaction, Desquamation...
Other AEs:
Hand and foot skin reaction (10%)
Desquamation (5%)
Fatigue (12.5%)
Hypertension (5%)
Mucositis oral (2.5%)
Alopecia (12.5%)
Dry skin (12.5%)
Nausea (12.5%)
Vomiting (12.5%)
Anorexia (15%)
Weight loss (17.5%)
Hypocalcaemia (12.5%)
Sources:
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Other AEs: Hypertension, Fatigue...
Other AEs:
Hypertension (grade 3, 2%)
Fatigue (grade 3, 2%)
Fever (grade 3, <1%)
Weight loss (grade 3, <1%)
Rash (grade 3, 1%)
Hand and foot skin reaction (grade 3, 5%)
Pruritus (grade 3, <1%)
Flushing (grade 3, <1%)
Diarrhea (grade 3, 2%)
Nausea (grade 3, 1%)
Anorexia (grade 3, 1%)
Constipation (grade 3, 1%)
Vomiting (grade 3, <1%)
Mucositis (grade 3, <1%)
Infection (grade 3, 1%)
Cough (grade 3, <1%)
Dyspnea (grade 3, 2%)
Dyspnea (grade 4, <1%)
Hypertension (grade 4, <1%)
Fatigue (grade 4, <1%)
Lymphopenia (grade 3, 5.1%)
Amylase increased (grade 3, 2.4%)
Hyperglycemia (grade 3, 4.1%)
Hyperkalemia (grade 3, 2.1%)
Lipase increased (grade 3, 3.5%)
Hyponatremia (grade 3, 3.5%)
Hypophosphatemia (grade 3, 1.8%)
Lymphopenia (grade 4, 0.6%)
Amylase increased (grade 4, 0.6%)
Hyperglycemia (grade 4, 0.3%)
Hyperkalemia (grade 4, 0.6%)
Lipase increased (grade 4, 1.8%)
Sources:
100 mg 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources:
unhealthy, Median age 60 years
Health Status: unhealthy
Age Group: Median age 60 years
Sex: M+F
Sources:
DLT: Diarrhea...
Dose limiting toxicities:
Diarrhea (grade 3, 20%)
Sources:
400 mg 2 times / day multiple, oral
MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 60 years
Health Status: unhealthy
Age Group: Median age 60 years
Sex: M+F
Sources:
Disc. AE: Pancreatitis...
AEs leading to
discontinuation/dose reduction:
Pancreatitis (grade 3, 6.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anorexia grade 1, 33%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Nausea grade 1, 33%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Pharyngitis grade 1, 33%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Fatigue grade 1, 67%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Pruritis grade 1, 67%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Rash grade 2, 33%
DLT, Disc. AE
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Dyspnea grade 3, 33%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Dyspnea grade 3, 33%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Hypertension grade 3, 33%
DLT, Disc. AE
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Rash grade 3, 67%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Rash grade 3, 67%
DLT, Disc. AE
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Hypocalcemia grade 1, 17%
600 mg 2 times / day multiple, oral
MTD
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Pruritis grade 1, 17%
600 mg 2 times / day multiple, oral
MTD
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Rash grade 1, 17%
600 mg 2 times / day multiple, oral
MTD
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Constipation grade 3, 17%
600 mg 2 times / day multiple, oral
MTD
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Depressed level of consciousness grade 3, 17%
600 mg 2 times / day multiple, oral
MTD
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Hypoalbuminemia grade 3, 17%
600 mg 2 times / day multiple, oral
MTD
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Hypoxia grade 3, 17%
600 mg 2 times / day multiple, oral
MTD
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Muscle weakness grade 3, 17%
600 mg 2 times / day multiple, oral
MTD
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Obstruction ureter grade 3, 17%
600 mg 2 times / day multiple, oral
MTD
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Pleural effusion grade 3, 17%
600 mg 2 times / day multiple, oral
MTD
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Alkaline phosphatase grade 3, 33%
600 mg 2 times / day multiple, oral
MTD
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Ascites grade 3, 33%
600 mg 2 times / day multiple, oral
MTD
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, Mean age 53.7 years
Health Status: unhealthy
Age Group: Mean age 53.7 years
Sex: M+F
Sources:
Diarrhea 22.5%
800 mg 2 times / day multiple, oral
Highest studied dose
unhealthy, Median age 57 years
Hand and foot skin reaction 10%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Median age 57 years
Alopecia 12.5%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Median age 57 years
Dry skin 12.5%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Median age 57 years
Fatigue 12.5%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Median age 57 years
Hypocalcaemia 12.5%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Median age 57 years
Nausea 12.5%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Median age 57 years
Vomiting 12.5%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Median age 57 years
Anorexia 15%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Median age 57 years
Weight loss 17.5%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Median age 57 years
Mucositis oral 2.5%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Median age 57 years
Desquamation 5%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Median age 57 years
Hypertension 5%
800 mg 2 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources:
unhealthy, Median age 57 years
Anorexia grade 3, 1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Constipation grade 3, 1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Infection grade 3, 1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Nausea grade 3, 1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Rash grade 3, 1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Hypophosphatemia grade 3, 1.8%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Diarrhea grade 3, 2%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Dyspnea grade 3, 2%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Fatigue grade 3, 2%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Hypertension grade 3, 2%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Hyperkalemia grade 3, 2.1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Amylase increased grade 3, 2.4%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Hyponatremia grade 3, 3.5%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Lipase increased grade 3, 3.5%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Hyperglycemia grade 3, 4.1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Hand and foot skin reaction grade 3, 5%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Lymphopenia grade 3, 5.1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Cough grade 3, <1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Fever grade 3, <1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Flushing grade 3, <1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Mucositis grade 3, <1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Pruritus grade 3, <1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Vomiting grade 3, <1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Weight loss grade 3, <1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Hyperglycemia grade 4, 0.3%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Amylase increased grade 4, 0.6%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Hyperkalemia grade 4, 0.6%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Lymphopenia grade 4, 0.6%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Lipase increased grade 4, 1.8%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Dyspnea grade 4, <1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Fatigue grade 4, <1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Hypertension grade 4, <1%
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 58 years
Health Status: unhealthy
Age Group: Median age 58 years
Sex: M+F
Sources:
Diarrhea grade 3, 20%
DLT
100 mg 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources:
unhealthy, Median age 60 years
Health Status: unhealthy
Age Group: Median age 60 years
Sex: M+F
Sources:
Pancreatitis grade 3, 6.7%
Disc. AE
400 mg 2 times / day multiple, oral
MTD
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
unhealthy, Median age 60 years
Health Status: unhealthy
Age Group: Median age 60 years
Sex: M+F
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
yes [IC50 0.84 uM]
yes [Ki 1.5 uM]
yes [Ki 1.5 uM]
yes [Ki 17 uM]
no (co-administration study)
Comment: Administration of NEXAVAR 400 mg twice daily for 28 days did not alter the exposure of concomitantly administered midazolam (CYP3A4 substrate), dextromethorphan (CYP2D6 substrate), or omeprazole (CYP2C19 substrate).
Page: -
yes [Ki 2.4 uM]
yes [Ki 4.2 uM]
no (co-administration study)
Comment: Administration of NEXAVAR 400 mg twice daily for 28 days did not alter the exposure of concomitantly administered midazolam (CYP3A4 substrate), dextromethorphan (CYP2D6 substrate), or omeprazole (CYP2C19 substrate).
Page: -
yes [Ki 4.9 uM]
no (co-administration study)
Comment: Administration of NEXAVAR 400 mg twice daily for 28 days did not alter the exposure of concomitantly administered midazolam (CYP3A4 substrate), dextromethorphan (CYP2D6 substrate), or omeprazole (CYP2C19 substrate).
Page: -
yes [Ki 6.2 uM]
yes [Ki 7.3 uM]
no (co-administration study)
Comment: The possible effect of sorafenib on a CYP2C9 substrate was assessed indirectly in patients receiving warfarin. The mean changes from baseline in PT-INR were not higher in NEXAVAR patients compared to placebo patients
Page: -
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
no (co-administration study)
Comment: Ketoconazole (400 mg), a potent inhibitor of CYP3 A4, administered once daily for 7 days did not alter the mean AUC of a single oral 50 mg dose of sorafenib in healthy volunteers. There is no clinical information on the effect of CYP3A4 inducers on the pharmacokinetics of sorafenib. Substances that are inducers of CYP3A4 activity are expected to increase metabolism of sorafenib and thus decrease sorafenib concentrations.
Page: -
no
no
no
no
no
no
no
no
no
no
yes [Km 5.8 uM]
yes
yes
yes
unlikely
Comment: The efflux ratio of sorafenib for transport from basolateral —> apical side to transport from the apical —> basolateral side of Caco-2 cells, ranged from 2.9 to 4.7. Given that sorafenib is highly permeable, the degree of efflux is not expected to result in an effect on overall absorption in man.
Page: -
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
BAY 43-9006: early clinical data in patients with advanced solid malignancies.
2002
Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
2003 Dec
Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006.
2003 Dec
Gateways to clinical trials.
2004 Apr
B-RAF is a therapeutic target in melanoma.
2004 Aug 19
Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.
2004 Jun 1
How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.
2004 Nov
Novel agents for the treatment of advanced kidney cancer.
2004 Oct
Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum.
2004 Sep 25
Improving outcomes in advanced malignant melanoma: update on systemic therapy.
2005
Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1.
2005 Apr
Raf kinase as a target for anticancer therapeutics.
2005 Apr
Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?
2005 Aug 16
Raf kinase inhibitors in oncology.
2005 Feb
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.
2005 Feb
Multi-kinase inhibitors create buzz at ASCO.
2005 Jun
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
2005 Mar
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
2005 Mar 15
Angiogenesis and lung cancer: prognostic and therapeutic implications.
2005 May 10
Update on angiogenesis inhibitors.
2005 Nov
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
2005 Oct
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.
2005 Oct 20
Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
2005 Sep
Spinal cord metastasis of a non-neurofibromatosis type-1 malignant peripheral nerve sheath tumor: an unusual manifestation of a rare tumor.
2005 Sep
Raf: a strategic target for therapeutic development against cancer.
2005 Sep 20
Drug approval triggers debate on future direction for cancer treatments.
2006 Feb
Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication.
2006 Jan 23
Targeting Raf-kinase: molecular rationales and translational issues.
2006 Jun
VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
2006 Mar
Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants.
2006 Oct 26
Patents

Sample Use Guides

The recommended daily dose of NEXAVAR (tosylate salt of sorafenib) is 400 mg (2 x 200 mg tablets) taken twice daily, without food (at least 1 hour before or 2 hours after eating). Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. 432 433 434 435 436 437 438 439 Management of suspected adverse drug reactions may require temporary interruption and/or dose reduction of NEXAVAR therapy. When dose reduction is necessary, the NEXAVAR dose may be reduced to 400 mg once daily. If additional dose reduction is required, NEXAVAR may be reduced to a single 400 mg dose every other day
Route of Administration: Oral
Patient-derived glioblastoma cells with low concentrations of sorafenib caused a dramatic dose dependent inhibition of proliferation (IC(50), 1.5 microM) and induction of apoptosis and autophagy. Sorafenib inhibited phosphorylation of signal transducer and activator of transcription 3 (Stat3) and expression of cyclins, D and E. In contrast, AKT was not modulated by sorafenib
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:24:38 GMT 2025
Edited
by admin
on Mon Mar 31 21:24:38 GMT 2025
Record UNII
9ZOQ3TZI87
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SORAFENIB
EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
BAY 43-9006
Preferred Name English
SORAFENIB [USAN]
Common Name English
SORAFENIB [MART.]
Common Name English
SORAFENIB [EMA EPAR]
Common Name English
2-PYRIDINECARBOXAMIDE, 4-(4-((((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)AMINO)CARBONYL)AMINO)PHENOXY)-N-METHYL-
Systematic Name English
SORAFENIB [MI]
Common Name English
4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N(SUP 2)-METHYLPYRIDINE-2-CARBOXAMIDE
Systematic Name English
Sorafenib [WHO-DD]
Common Name English
SORAFENIB [VANDF]
Common Name English
BAY-43-9006
Code English
sorafenib [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
WHO-VATC QL01XE05
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
NCI_THESAURUS C1742
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
WHO-ATC L01XE05
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
NDF-RT N0000175076
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
FDA ORPHAN DRUG 675918
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
FDA ORPHAN DRUG 220206
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
FDA ORPHAN DRUG 185204
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
EMA ASSESSMENT REPORTS NEXAVAR (AUTHORIZED: CARCINOMA, HEPATOCELLULAR, CARINOMA, RENAL CELL)
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
FDA ORPHAN DRUG 320310
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
LIVERTOX NBK548944
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
FDA ORPHAN DRUG 229206
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
NDF-RT N0000175605
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
NCI_THESAURUS C1404
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
Code System Code Type Description
INN
8234
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
RXCUI
495881
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY RxNorm
LACTMED
Sorafenib
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
NCI_THESAURUS
C61948
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
MESH
C471405
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
PUBCHEM
216239
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
EPA CompTox
DTXSID7041128
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
USAN
UU-02
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
WIKIPEDIA
SORAFENIB
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
ChEMBL
CHEMBL1336
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
HSDB
8173
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
IUPHAR
5711
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
DRUG BANK
DB00398
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
DRUG CENTRAL
2459
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
FDA UNII
9ZOQ3TZI87
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
MERCK INDEX
m10116
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY Merck Index
CHEBI
50924
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
SMS_ID
100000091433
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
CAS
284461-73-0
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
EVMPD
SUB23139
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
DAILYMED
9ZOQ3TZI87
Created by admin on Mon Mar 31 21:24:38 GMT 2025 , Edited by admin on Mon Mar 31 21:24:38 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
TRANSPORTER -> INHIBITOR
TARGET -> INHIBITOR
IC50
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
FECAL
METABOLITE ACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
METABOLITE -> PARENT
FECAL
METABOLITE -> PARENT
PLASMA
Related Record Type Details
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC